Harnessing anticalin technology as a multi-targeted treament approach for vision loss [ 2017 - 2019 ]

Research Grant

Researchers: Prof Jennifer Wilkinson-Berka (Principal investigator) ,  A/Pr Lyndell Lim ,  Prof Gary Anderson

Brief description Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.

Funding Amount $AUD 641,636.43

Funding Scheme Development Grants

Notes Development Grant